The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2024 | Evolution of risk stratification in SMM & MGUS: CTCs & imaging techniques
In this discussion, Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discuss novel technologies being explored to risk stratify individuals with smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). The experts highlight limitations of the 2/20/20 model, and further share insights into the value of circulating tumor cells (CTCs) and imaging techniques in clinical practice. This session was filmed at IBC 2024, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
